Pharma and biotech

Our broad portfolio of solutions has helped us develop strong partnerships with a variety of organisations, including top-20 pharmaceutical companies and newly launched biotechs. We adapt our support to the identified needs and regulatory requirements of each partner. Our team of scientists strive to empower our clients throughout the complex drug development process by rapidly developing and maximising the value of the IP and assets our partners put in our hands. 

For pharmaceutical and biotech companies, we offer tailored solutions that address the specific needs and challenges of drug discovery and development. With over 40 years of industry expertise, our team of scientists — many of whom have extensive experience in the pharma sector — bring a deep understanding of the intricacies involved in the projects they support. Our services are designed to integrate seamlessly into our clients´ workflow at any stage, from initial target identification to clinical trials. We provide flexible entry and exit points, helping ensure that our solutions enhance your project’s value and streamline your research process. Our clients have included Vertex Pharmaceuticals, Merck KGaA, Bayer Pharma, Plectonic Biotech, Tilikum Therapeutics, Molecure SA, BioVersys, Vaderis Therapeutics, Immunic Therapeutics and many others.  

Venture capitals

De-risking compounds is crucial to bring innovative therapies to patients quickly and efficiently. We are committed to partnering with you to share and mitigate these risks. Nuvisan supports company building from the very early stages, acting both as specialist consultants for R&D and as executive partners for drug discovery and development. At our Centre of Excellence – Discovery in Berlin, formed originally as part of the drug discovery unit of Bayer Pharmaceutical, we offer comprehensive services from target identification and validation to IND-enabling studies under GLP, including hit identification, hit-to-lead, lead optimisation and DMPK profiling. As scientific consultants, we can: 

• De-risk projects and portfolios with tailored go/no-go experiments.
• Provide selective support from expert staff during the development phase.
• Offer expertise from professionals routinely working with big pharma, biotech and regulatory authorities (BfARM, PEI, Ethics Commission and more).
• Advise on reaching key pharma milestones for potential partnering.
• Develop efficient research plans to address future challenges.
• Evaluate reproducibility with wet lab activities to generate high-quality, timely and unbiased results.

Our teams support venture capitalists from the due diligence stage, offering:

• Evaluation of early ideas (proof-of-principle).
• Participation in investor – company discussions with independent field specialists.
• Assessment of compound specifics and chances of success based on existing experiences.
• Evaluation of existing data for trustworthiness, plausibility and necessary scope.
• Verification of milestone planning and timing.
• Cost calculation for milestones, including regulatory affairs and laboratory costs.
• Confidential reference to relevant experiences, including failures.

 

Non-profits and research institutions

Our teams are dedicated to advancing the frontiers of medical science and addressing global health challenges. We recognise the invaluable contributions of non-profit organisations and academic institutions in pioneering basic research and tackling the complexities of neglected diseases. By collaborating with these entities, we aim to support groundbreaking research efforts and expedite the development of much-needed therapies. Examples of non-profits and research institutions include: the Gates Foundation, which we support with services in the non-hormonal contraceptive research area; our participation in the Critical Assessment of Computational Hit-finding Experiments (CACHE) consortium, which seeks to enhance in silico hit identification methods for understudied biological targets using computational techniques; our oncology services supporting the research at the Deutsches Krebsforschungszentrum (DKFZ); and our commitment to the Corona Accelerated R&D in Europe (IMI-Care) consortium.